Ionis Pharmaceuticals Inc (IONS) is near the bottom in its industry group according to InvestorsObserver. IONS gets an overall rating of 26. That means it scores higher than 26 percent of stocks. Ionis Pharmaceuticals Inc gets a 15 rank in the Biotechnology industry. Biotechnology is number 30 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 26 means the stock is more attractive than 26 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Ionis Pharmaceuticals Inc (IONS) stock has fallen -0.68% while the S&P 500 has risen 0.09% as of 12:10 PM on Thursday, Dec 24. IONS has fallen -$0.41 from the previous closing price of $60.27 on volume of 784,407 shares. Over the past year the S&P 500 is up 13.99% while IONS has fallen -2.62%. IONS earned $0.49 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 121.29.

Click Here to get the full Stock Score Report on Ionis Pharmaceuticals Inc (IONS) Stock.

Visit link:
Is Ionis Pharmaceuticals Inc (IONS) a Winner in the Biotechnology Industry? - InvestorsObserver